Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma [0.03%]
一项关于免疫细胞因子simlukafusp alfa（FAP-IL2v）与西妥昔单抗联合治疗头颈部鳞状细胞癌的IIb期研究
Aaron R Hansen,Carlos A Gomez-Roca,Debbie G J Robbrecht et al.
Aaron R Hansen et al.
Purpose: This phase Ib trial evaluated fibroblast activation protein-α-targeted IL2 variant (FAP-IL2v), a novel immunocytokine engineered to minimize CD25-mediated toxicities, in combination with cetuximab, in patients w...
Sarah Samorodnitsky,Megan Othus,Michael LeBlanc et al.
Sarah Samorodnitsky et al.
Evaluating a novel treatment in a randomized controlled trial requires comparison against existing therapies. If several existing therapies of similar benefit exist, the identification of a single control regimen may be difficult. For this ...
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies [0.03%]
fianlimab（抗lag-3抗体）与cemiplimab联合治疗晚期恶性肿瘤的首个人体剂量递增研究
Nehal J Lakhani,Kyriakos P Papadopoulos,Melissa Lynne Johnson et al.
Nehal J Lakhani et al.
Purpose: Preclinical data indicate that fianlimab (antilymphocyte activation gene-3) plus cemiplimab (anti-PD-1) enhances antitumor activity. Here, we report prespecified final analyses of the dose-escalation part of a fi...
Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma [0.03%]
T细胞和B细胞的空间动力学可预测可切除与不可切除的肝细胞癌的临床结局
Yutaka Kurebayashi,Katsutoshi Sugimoto,Hanako Tsujikawa et al.
Yutaka Kurebayashi et al.
Purpose: Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their dif...
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer [0.03%]
SWOG/NCI罕见肿瘤二期抗CTLA-4/PD-1联合治疗：非上皮性卵巢癌
Young Kwang Chae,Megan Othus,Sandip Pravin Patel et al.
Young Kwang Chae et al.
Purpose: The role of dual checkpoint inhibition (ipilimumab at 1 mg/kg intravenously every 6 weeks and nivolumab at 240 mg intravenously every 2 weeks) in advanced rare/ultrarare nonepithelial ovarian cancers is yet to be...
Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer [0.03%]
晚期子宫内膜癌患者血浆ctDNA的全景视图及其预后因素分析
Pamela Soberanis Pina,Keelia Clemens,Adrian Bubie et al.
Pamela Soberanis Pina et al.
Purpose: ctDNA is a novel technique extensively studied in solid tumors, although not currently well defined in endometrial cancer. Experimental design: ...
Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced Melanoma [0.03%]
可手术的局部区域晚期黑色素瘤患者中应用瘤内电转IL-12质粒联合纳武利尤单抗的新辅助治疗研究
Ahmad A Tarhini,Zeynep Eroglu,Islam Eljilany et al.
Ahmad A Tarhini et al.
Purpose: Intratumoral tavokinogene telseplasmid delivered by electroporation (TAVO-EP) results in localized expression of IL-12 within the tumor microenvironment (TME). This study evaluated neoadjuvant TAVO-EP combined wi...
Tumor Hypoxia: Long Ignored but Now Detectable and Potentially Actionable [0.03%]
肿瘤低氧状态：长期被忽略但现在已经可以检测并有望进行干预
Ralph P Mason
Ralph P Mason
Oxygen-enhanced MRI was successfully applied to 24 patients with human papillomavirus-associated oropharyngeal cancer. This prospective trial rigorously evaluated reproducibility and changes with respect to tumor radiation. Analyses compare...
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma [0.03%]
Teclistamab-A双特异性CD3T细胞衔接器用于复发或难治性多发性骨髓瘤的FDA批准概要
Andrea C Baines,Bindu Kanapuru,Jay Zhao et al.
Andrea C Baines et al.
On October 25, 2022, the FDA granted accelerated approval to teclistamab-cqyv (TECVAYLI; Janssen Biotech) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therap...
Large-Scale Comparative Analysis of Canine and Human Osteosarcomas Uncovers Conserved Clinically Relevant Tumor Microenvironment Subtypes [0.03%]
大规模犬和人骨肉瘤比较分析发现保守的临床相关肿瘤微环境亚型
Sushant Patkar,Joshua Mannheimer,Stephanie A Harmon et al.
Sushant Patkar et al.
Purpose: Osteosarcoma is an aggressive bone cancer lacking robust biomarkers for personalized treatment. Despite its scarcity in humans, it is relatively common in adult pet dogs. This study aimed to analyze clinically an...